TEC-001 (with TATE)
Colorectal Cancer
About Teclison
Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.
View full company profileAbout Teclison
Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.
View full company profileAbout Teclison
Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CY-101 + Pembrolizumab | Cytovation | Phase 1/2 |
| M9140 | Merck KGaA | Phase 1/2 |
| Repositioned/Rerouted API | Reponex | Not Specified |
| Leronlimab | CytoDyn | Phase 2 |
| EGFR inhibitor | Acellera | Pre-clinical |
| Cannabics® RCC-33 | CNBX Pharmaceuticals | Preclinical |
| VCR-036 | Vicero Bio | Preclinical |
| CBI-1214 | Cartography Biosciences | Phase 1 |
| QL335 | QLSF Biotherapeutics | Phase 1 |
| Colorectal Cancer Detection Partnership | Daisy Genomics | Research/Assay Development |
| High Internalization ADC | Lytica Therapeutics | Preclinical |
| Undisclosed Colorectal Program(s) | Tavanta Therapeutics | Phase 2 |